- Home
- PED vs MAIA Comparison
PED vs MAIA Comparison
Compare PED & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | MAIA |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PED | MAIA |
|---|---|---|
| Price | $0.56 | $1.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | 154.1K | ★ 1.0M |
| Earning Date | 11-17-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $33,244,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | N/A |
| P/E Ratio | $5.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.87 |
| 52 Week High | $1.00 | $2.74 |
Technical Indicators
Market Signals| Indicator | PED | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 56.09 |
| Support Level | $0.54 | $1.13 |
| Resistance Level | $0.57 | $1.75 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 59.60 | 47.58 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.